

Date: 14th November, 2024

To,

Listing Compliances, BSE Limited , P. J. Towers, Fort, Mumbai - 400001. Scrip Code: 539938; Scrip Id: MIL	Listing Compliances, CSE - India , 7, Lyons Range, Dalhousie Kolkata - 700001.
---	--

Subject: Outcome of Board Meeting and Compliances of Regulation 30, 33 and 42 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015.

Dear Sir/Ma'am,

Pursuant to provisions of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, this is to inform you that the Board of Directors of the Company at its meeting held today i.e., November 14, 2024, inter alia, considered and approved Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and half year ended on September 30, 2024 along with Limited Review Report issued by M/s. V Goswami & Co, Statutory Auditors of the Company.

Further, please find enclosed "Standalone and Consolidated Unaudited Financial Results, Statement of Assets and Liabilities and Cash Flow Statement along with Limited Review Report" for the quarter and half year ended on September 30, 2024 as **Annexure 1** and same is also available on the website of the Company viz. www.medicointercontinental.com

The Board Meeting of the Company commenced at 12:30 PM and concluded at 01:50 PM.

This is for your information and records.

Thanking You,

FOR MEDICO INTERCONTINENTAL LIMITED



Puneeta Sharma
Company Secretary & Compliance Officer



V.GOSWAMI & CO.
CHARTERED ACCOUNTANTS

RBI UCN NO. :- 897783

C&AG REG NO. :- WR4659

MSME :- GJ01D0134595

GST :- 24AAHFV3075F1Z7

3, SF, Manek Appt, Nr. Jain Derasar, B/s. Tagor Park, Nehrunagar Circle, Ahmedabad - 380015.
M : +91 94287 33430, +91 97247 28711 | E-mail : thegoswami@gmail.com | www.goswami.in

Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Standalone Financial Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015(as amended)

TO THE BOARD OF DIRECTORS OF MEDICO INTERCONTINENTAL LIMITED


We have reviewed the accompanying Statements of Standalone Unaudited Financial Results of MEDICO INTERCONTINENTAL LIMITED ("the company"), for the quarter ended September 30, 2024 ("the Statement") and year to date from April 01, 2024 to September 30, 2024 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For, V. GOSWAMI & CO,
Chartered Accountants
(FRN:0128769W)


Vipul Goswami
(Partner)

Mem. No: 119809

Date: - 14/11/2024

Place:-Ahmedabad

UDIN: 24119809BKDTFD7475



MEDICO INTERCONTINENTAL LIMITED							
CIN NO: L24100GJ1984PLC111413							
Regd. Off: 1-5th FLOOR, ADIT RAJ ARCADE NR KARMA, SHRESHTHA TOWER, 100 FT RD, SATELLITE, AHMEDABAD - 380015, GUJARAT IN							
Tel No. 079-26742739 E-mail:- mail@medicointercontinental.com Website: www.medicointercontinental.com							
Statement of Standalone Unaudited Financial Results for the Quarter and Half year ended September 30, 2024							
(Rs. in Lakhs)							
Sr. No.	Particulars	Quarter Ended			Half Year Ended		Year Ended
		3 Months ended	Preceding 3 Months ended	Corresponding 3 months ended in previous year on	Year to date figure for current period ended	Year to date figure for previous period ended	Previous Year ended
		30.09.2024	30.06.2024	30.09.2023	30.09.2024	30.09.2023	31.03.2024
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
	Revenues						
1	Revenue from Operations	2893.73	1151.99	981.19	4045.72	2671.29	4403.68
2	Other Income	9.79	10.32	23.65	20.11	29.32	41.66
3	Total Revenue (A)	2903.51	1162.32	1004.84	4065.83	2700.62	4445.34
	Expenses						
(a)	Cost of materials consumed	0.00	0.00	0.00	0.00	0.00	0.00
(b)	Purchases of stock-in-trade	2136.24	949.63	867.71	3085.87	2255.04	3746.44
(c)	Changes in inventories of finished goods and stock-in-trade	212.33	48.02	-56.60	260.35	11.51	-88.16
(d)	Employee benefits expense	37.45	37.51	45.05	74.96	70.81	158.80
(e)	Finance costs	17.88	9.49	1.62	27.37	6.70	22.29
(f)	Depreciation and amortisation expense	14.74	2.81	4.50	17.55	8.79	17.83
(g)	Other expenses	340.35	46.46	76.97	386.81	216.29	325.72
	Total Expenses (B)	2758.99	1093.92	939.26	3852.91	2569.14	4182.91
5	Profit/(Loss) before exceptional items & tax (1-4)	144.53	68.40	65.58	212.92	131.48	262.44
6	Exceptional items	0.00	0.00	0.00	0.00	0.00	0.00
7	Profit/(Loss) for the period from operations before tax (5+6)	144.53	68.40	65.58	212.92	131.48	262.44
8	Tax expense	45.63	18.68	17.95	64.32	35.85	72.73
(a)	Current Tax	39.10	19.03	18.61	58.13	37.11	75.38
(b)	Deferred Tax	6.53	-0.35	-0.66	6.19	-1.26	-2.65
9	Profit/(Loss) for the period from continuing operations (7-8)	98.89	49.71	47.63	148.61	95.63	189.70
10	Profit/(loss) for the period from discontinued operations	0.00	0.00	0.00	0.00	0.00	0.00
11	Tax expense of discontinued operations	0.00	0.00	0.00	0.00	0.00	0.00
12	Profit/(loss) for the period from Discontinued operations (after tax)	0.00	0.00	0.00	0.00	0.00	0.00
13	Profit/ (loss) for the period (After tax)	98.89	49.71	47.63	148.61	95.63	189.70
14	Other Comprehensive Income						
	Other comprehensive Income/(Loss)	0.00	0.00	0.00	0.00	0.00	0.00
15	Total Comprehensive Income for the period (13+14)	98.89	49.71	47.63	148.61	95.63	189.70
	Paid-up Equity Share Capital (Face Value INR 10 each)	1000.00	1000.00	1000.00	1000.00	1000.00	1000.00
16	Earnings Per Equity Share of Rs. 10 each (for continuing Operations)						
(a)	Basic - INR	0.99	0.50	0.48	1.49	0.96	1.90
(b)	Diluted - INR	0.99	0.50	0.48	1.49	0.96	1.90
17	Earnings Per Equity Share of Rs. 10 each (for discontinuing Operations)						
(a)	Basic - INR	0.00	0.00	0.00	0.00	0.00	0.00
(b)	Diluted - INR	0.00	0.00	0.00	0.00	0.00	0.00
18	Earnings Per Equity Share of Rs. 10 each (for continuing & discontinuing Operations)						
(a)	Basic - INR	0.99	0.50	0.48	1.49	0.96	1.90
(b)	Diluted - INR	0.99	0.50	0.48	1.49	0.96	1.90

1 The above unaudited standalone financial results of the Company for the quarter and half year ended September 30, 2024 have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on November 14, 2024. The above results reviewed by statutory auditors and who have expressed an unmodified opinion on these results.


2 These results have been prepared in accordance with the Ind AS notified under the Companies (Indian Accounting Standards) Rules 2015 as amended from time to time.


3 During the quarter ended September 30, 2024, the company is operating in single segment. So segment reporting is not applicable for this quarter, but segment information shall provides as and when the same shall be operative.

4 The Company has continued with old Income Tax rates for the current quarter and is evaluating the impact of the new rates under section 115 BAA of the Income Tax Act, 1961 as per the Taxation Laws (Amendment) Ordinance, 2019.

5 The previous period figures have been re-grouped / reclassified, wherever considered necessary.

Place: Ahmedabad
Date: 14/11/2024



For and on behalf of Board of Directors of
Medico Intercontinental Limited

TANVISHAH
Chairperson
DIN: 08192047

MEDICO INTERCONTINENTAL LIMITED

CIN: L24100GJ1984PLC111413

Regd. Off: 1-5th FLOOR, ADIT RAJ ARCADE NR KARMA, SHRESHTHA TOWER, 100 FT RD, SATELLITE, AHMEDABAD - 380015, GUJARAT IN

Tel No. 079-26742739

E-mail:- mail@medicointercontinental.com

Website: www.medicointercontinental.com

Unaudited Standalone Statement of Assets and Liabilities as at 30 September, 2024

(Rs in Lakhs)

Particulars		As at 30.09.2024	As at 31.03.2024
		Unaudited	Audited
A. ASSETS			
1 Non-current assets			
Property, Plant and Equipments		202.59	33.11
Financial Assets			
(i) Investments		582.22	420.19
Deferred Tax Assets (Net)		1.32	7.50
Other Non-Current Assets			
Total Non-Current Assets		1,281.82	1,281.82
2 Current assets			
Inventories		196.54	456.89
Financial Assets			
(i) Trade receivables		2,208.13	1,492.51
(ii) Cash and Cash Equivalents		299.35	240.54
(iii) Loans		96.47	-
Other Current Assets		3.62	11.61
Total Current Assets		2,804.12	2,201.55
TOTAL ASSETS		4,872.07	3,944.18
B. EQUITY AND LIABILITIES			
1 Equity			
Equity Share Capital		1,000.00	1,000.00
Other Equity		2,758.18	2,609.57
Total Equity		3,758.18	3,609.57
Liabilities			
2 Non-Current Liabilities			
Financial Liabilities			
(i) Borrowings		690.47	79.79
(ii) Lease liability			
(iii) Other financial liabilities			
Long term provisions			
Deferred tax liabilities (Net)		8.18	6.60
Other non-current liabilities			
Total Non-Current Liabilities		698.65	86.40
3 Current Liabilities			
Financial Liabilities			
(i) Borrowings		91.98	16.67
(ii) Trade Payables		-	-
Due to Micro and Small Enterprises		162.30	102.03
Due to others		53.56	91.42
(iii) Other Financial Liabilities		-	-
Other Current Liabilities		81.72	7.87
Current tax liabilities (net)		25.68	29.74
Short term provisions		-	0.48
Total Current Liabilities		415.24	248.21
TOTAL EQUITY AND LIABILITIES		4,872.07	3,944.18

For and on behalf of Board of Directors of
MEDICO INTERCONTINENTAL LIMITED



Tanvi

TANVI SHAH
Chairperson
DIN: 08192047

Place:- Ahmedabad
Date:-14/11/2024

MEDICO INTERCONTINENTAL LIMITED

CIN: L24100GJ1984PLC111413

Regd. Off: 1-5th FLOOR, ADIT RAJ ARCADE NR KARMA, SHRESHTHA TOWER, 100 FT RD, SATELLITE, AHMEDABAD - 380015, GUJARAT IN
Tel No. 079-26742739 E-mail:- mail@medicointercontinental.com Website: www.medicointercontinental.com

Unaudited Standalone Cash Flow Statement for the half year ended 30 September, 2024

(Rs in Lakhs)

PARTICULARS		Half year ended 30.09.2024 (Unaudited)	Half year ended 30.09.2023 (Unaudited)
A.	CASH FLOW FROM OPERATING ACTIVITIES :		
a)	Net Profit/ (Loss) before tax	212.92	131.48
b)	OPERATING PROFIT BEFORE WORKING CAPITAL CHANGES	212.92	131.48
	<u>Adjustments For:</u>		
	Depreciation	17.55	8.79
	Finance costs	27.37	6.70
	Interest and Dividend Income	-10.79	-21.65
	CASH GENERATED FROM OPERATIONS	247.05	125.31
	<u>Adjustments for</u>		
	Decrease/(Increase) in Inventories	260.35	11.51
	Decrease/(Increase) in Trade Receivables	-715.62	772.26
	Decrease/(Increase) in Other Current assets	7.99	-14.05
	Increase/(Decrease) in Provisions	0.00	0.00
	Increase/(Decrease) in Trade Payables	22.40	-400.10
	Increase/(Decrease) in Current Financial Liabilities - Borrowings	0.00	0.00
	Increase/(Decrease) in Other Current Liabilities	73.85	-9.96
	CASH GENERATION FROM OPERATING ACTIVITY	-103.98	484.98
	Income Tax Paid Net	(62.19)	(49.52)
	NET CASH FROM/(USED IN) OPERATING ACTIVITIES	-166.16	435.47
B.	CASH FLOW FROM INVESTING ACTIVITIES:		
	Purchase of Fixed Assets	-187.03	-3.13
	Decrease/(Increase) in Investment	-162.03	0.00
	Gratuity Expenses	1.10	0.90
	Interest and Dividend Income	10.79	21.65
	Other Non-Current Assets	0.00	-569.19
	NET CASH FROM/(USED IN) INVESTING ACTIVITIES	-337.16	-549.78
C.	CASH FLOW FROM FINANCING ACTIVITIES:		
	Proceeds from issue of Shares	-	-
	Increase/(Decrease) in Loans and Advances	-96.47	-86.48
	Proceed from /(Repayment) of Borrowings net	610.67	87.22
	Proceed from /(Repayment) of Short Term Borrowings net	75.31	0.00
	Dividend Paid	0.00	-10.00
	Finance Costs paid	-27.37	-6.70
	NET CASH FROM/(USED IN) FINANCING ACTIVITIES	562.14	-15.96
	NET INCREASE IN CASH AND CASH EQUIVALENTS	58.81	-130.27
	CASH AND CASH EQUIVALENTS (At the beginning of the year)	240.54	494.95
	CASH AND CASH EQUIVALENTS (At the end of the year)	299.35	364.68

For and on behalf of Board of Directors of
MEDICO INTERCONTINENTAL LIMITED



Tanvi

TANVI SHAH
Chairperson
DIN: 08192047

Place:- Ahmedabad
Date:- 14/11/2024



3, SF, Manek Appt, Nr. Jain Derasar, B/s. Tagor Park, Nehrunagar Circle, Ahmedabad - 380015.
M : +91 94287 33430, +91 97247 28711 | E-mail : thegoswami@gmail.com | www.goswami.in

Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Consolidated Financial Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

TO THE BOARD OF DIRECTORS OF MEDICO INTERCONTINENTAL LIMITED

We have reviewed the accompanying Statements of Consolidated Unaudited Financial Results of MEDICO INTERCONTINENTAL LIMITED ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), for the quarter ended September 30, 2024 ("the Statement") and year to date from April 01, 2024 to September 30, 2024 attached herewith, being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of the Parent Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

The Statement included the results of following subsidiary and joint venture company:-

1. EVAGRACE PHARMA PRIVATE LIMITED
2. RITZ FORMULATIONS PRIVATE LIMITED
3. SUNGRACE PHARMA PRIVATE LIMITED
4. AZILLIAN HEALTHCARE PRIVATE LIMITED
5. MEDICO LAB (Joint Venture)





V.GOSWAMI & CO.

CHARTERED ACCOUNTANTS

RBI UCN NO. :- 897783
C&AG REG NO. :- WR4659
MSME :- GJ01D0134595
GST :- 24AAHFV3075F1Z7

3, SF, Manek Appt, Nr. Jain Derasar, B/s. Tagor Park, Nehrunagar Circle, Ahmedabad - 380015.
M : +91 94287 33430, +91 97247 28711 | E-mail : thegoswami@gmail.com | www.goswami.in

Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 7 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

We did not review the interim financial results of the subsidiaries and joint venture included in the consolidated unaudited financial results, whose financial results and other unaudited financial information reflects total assets of Rs. 2799.54 Lakhs as at September 30, 2024, total revenues of Rs. 1189.29 Lakhs and Rs. 2075.70 Lakhs and total net profit Rs. 72.28 Lakhs and Rs.131.78Lakhs for quarter ended September 30, 2024 and for the period from April 01, 2024 to September 30, 2024, respectively, net cash inflow of Rs. 293.82 Lakhs for the period from April 01, 2024 to September 30,2024, respectively as considered in the Statement whose financial results have not been reviewed by us. These interim financial results have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of the subsidiaries, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above. Our conclusion on the Statement is not modified in respect of these matters.

For, V. GOSWAMI & CO,
Chartered Accountants
(FRN: 0128769W)

Vipul Goswami
(Partner)

Mem. No.: 119809

Date:-14/11/2024

Place: - Ahmedabad

UDIN: 24119809BKDTFE2670



MEDICO INTERCONTINENTAL LIMITED

CIN NO: L24100GJ1984PLC111413

Regd. Off: 1-5TH FLOOR, ADIT RAJ ARCADE NR KARMA SHRESHTHA TOWER, 100 FT RD, SATELLITE, Ahmedabad GJ 380015 IN
Tel No. 079-26742739 E-mail:- mail@medicointercontinental.com Website: www.medicointercontinental.com

Statement of Consolidated Unaudited Financial Results for the Quarter and Half Year ended September 30, 2024

(Rs in Lakhs)

Sr. No.	Particulars	Quarter Ended			Half Year Ended		Year Ended
		3 Months ended	Preceding 3 Months ended	Corresponding 3 months ended in previous year on	Year to date figure for current period ended	Year to date figure for previous period ended	Previous Year ended
		30.09.2024	30.06.2024	30.09.2023	30.09.2024	30.09.2023	31.03.2024
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
	Revenues						
1	Revenue from Operations	3723.81	1823.28	1712.30	5547.10	4140.24	7135.54
2	Other Income	4.10	12.69	8.25	16.79	16.61	40.14
3	Total Revenue (A)	3727.91	1835.98	1720.55	5563.89	4156.85	7175.69
4	Expenses						
	(a) Cost of materials consumed	0.00	0.00	0.00	0.00	0.00	0.00
	(b) Purchases of stock-in-trade	2654.46	1346.89	1263.94	4001.36	3139.28	5642.72
	(c) Changes in inventories of finished goods and stock-in-trade	231.78	77.9	61.88	309.70	179.11	-156.23
	(d) Employee benefits expense	111.30	92.45	94.03	203.75	166.67	391.60
	(e) Finance costs	28.30	17.62	9.46	45.92	20.74	49.31
	(f) Depreciation and amortisation expense	20.74	8.23	6.91	28.97	13.59	28.67
	(g) Other expenses	447.56	143.86	160.91	591.42	375.66	675.76
	Total Expenses (B)	3494.15	1686.97	1597.14	5181.12	3895.06	6631.84
5	Profit/(Loss) before exceptional items & tax (1-4)	233.76	149.01	123.41	382.77	261.79	543.85
6	Exceptional Items	0.00	0.00	0.00	0.00	0.00	0.00
7	Profit/(Loss) for the period from operations before tax (5+6)	233.76	149.01	123.41	382.77	261.79	543.85
8	Tax expense						
	(a) Current Tax	70.53	40.69	36.35	111.22	72.47	149.14
	(b) Deferred Tax	62.62	39.53	37.05	102.15	73.81	146.16
		7.92	1.16	-0.70	9.07	-1.34	2.98
9	Profit/(Loss) for the period from continuing operations (7-8)	163.23	108.32	87.06	271.55	189.32	394.71
10	Profit/(loss) for the period from discontinued operations	0.00	0.00	0.00	0.00	0.00	0.00
11	Tax expense of discontinued operations	0.00	0.00	0.00	0.00	0.00	0.00
12	Profit/(loss) for the period from Discontinued operations (after tax)	0.00	0.00	0.00	0.00	0.00	0.00
13	Profit/ (loss) for the period (After tax)	163.23	108.32	87.06	271.55	189.32	394.71
14	Other Comprehensive Income						
15	Total Comprehensive Income for the period (13+14)	163.23	108.32	87.06	271.55	189.32	394.71
	Paid-up Equity Share Capital (Face Value INR 10 each)	1000.000	1000.000	1000.000	1000.000	1000.000	1000.00
16	Earnings Per Equity Share of Rs. 10 each (for Continuing Operations)						
	(a) Basic - INR	1.63	1.08	0.87	2.72	1.89	3.95
	(b) Diluted - INR	1.63	1.08	0.87	2.72	1.89	3.95
17	Earnings Per Equity Share of Rs. 10 each (for Discontinuing Operations)						
	(a) Basic - INR	0.000	0.000	0.000	0.000	0.000	0.00
	(b) Diluted - INR	0.000	0.000	0.000	0.000	0.000	0.00
18	Earnings Per Equity Share of Rs. 10 each (for Continuing & Discontinuing Operations)						
	(a) Basic - INR	1.63	1.08	0.87	2.72	1.89	3.95
	(b) Diluted - INR	1.63	1.08	0.87	2.72	1.89	3.95

- The above unaudited Consolidated financial results of the Company for the quarter and half year ended September 30, 2024 have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on November 14, 2024. The above results reviewed by statutory auditors and who have expressed an unmodified opinion on these results.
- These results have been prepared in accordance with the Ind AS notified under the Companies (Indian Accounting Standards) Rules 2015 as amended from time to time.
- During the quarter ended September 30, 2024, the company is operating in single segment. So segment reporting is not applicable for this quarter, but segment information shall provides as and when the same shall be operative.
- The Company has continued with old Income Tax rates for the current quarter and is evaluating option available under section 115 BAA of the Income Tax Act, 1961 as per the Taxation Laws (Amendment) Ordinance, 2019.
- The key standalone financial information of the Company is given below:

Particulars	Quarter ended			Half year ended		Year ended
	30/09/2024	30/06/2024	30/09/2023	30/09/2024	30/09/2023	31/03/2024
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
Revenue from operations	2903.51	1162.32	1004.84	4065.83	2700.62	4445.34
Profit before tax	144.53	68.40	65.58	212.92	131.48	262.44
Net profit after tax	98.89	49.71	47.63	148.61	95.63	189.70
Total comprehensive income	98.89	49.71	47.63	148.61	95.63	189.70

- The previous period figures have been re-grouped / reclassified, wherever considered necessary.



For, Medico Intercontinental Limited

Tanvi

TANVI SHAH
Chairperson
DIN: 08192047

Place:- Ahmedabad
Date:- 14/11/2024

MEDICO INTERCONTINENTAL LIMITED

CIN: L24100GJ1984PLC111413

Regd. Off: 1-5TH FLOOR, ADIT RAJ ARCADE NR KARMA SHRESHTHA TOWER, 100 FT RD, SATELLITE, Ahmedabad GJ 380015 IN

Tel No. 079-26742739 E-mail:- mail@medicointercontinental.com Website: www.medicointercontinental.com

Unaudited Consolidated Statement of Assets and Liabilities as at September 30, 2024

(Rs in Lakhs)

Particulars	As at 30.09.2024	As at 31.03.2024
	Unaudited	Audited
A. ASSETS		
1 Non-current assets		
Property, Plant and Equipment	404.68	239.01
Intangible Assets	113.09	113.16
Financial Assets	-	-
(i) Investments	-	-
(ii) Loans	2.00	2.00
(iii) Other financial assets	-	-
Deffered tax assets (Net)	(0.00)	-
Other non-current Assets	-	-
Total Non-Current Assets	1,401.83	1,401.73
2 Current assets	1,921.59	1,755.90
Inventories	-	-
Financial Assets	735.10	1,043.97
(i) Trade Receivables	-	-
(ii) Cash and Cash Equivalents	3,223.74	2,320.61
(iii) Loans	624.11	336.52
Other Current Assets	96.47	-
Total Current Assets	118.28	147.24
TOTAL ASSETS	4,797.71	3,848.34
B. EQUITY AND LIABILITIES	6,719.31	5,604.25
1 Equity		
Equity Share capital	-	-
Other Equity	1,000.00	1,000.00
Share Application Money Pending Alloment	3,775.59	3,503.21
Total Equity	4,775.59	4,503.21
Liabilities		
2 Non-Current Liabilities		
Financial Liabilities	-	-
(i) Borrowings	718.72	186.97
(ii) Lease liability	-	-
(iii) Other financial liabilities	-	-
Long term provisions	-	-
Deferred tax liabilities (Net)	17.05	13.83
Other non-current liabilities	9.94	0.86
Total Non-current liabilities	0.30	0.30
3 Current liabilities	746.00	201.96
Financial Liabilities	-	-
(i) Borrowings	-	-
(iii) Trade Payables	274.83	298.47
Due to micor entepries and small enterprises	-	-
Due to others	213.07	123.46
(iv) Other financial liabilities	446.29	326.72
Other current liabilities	-	-
Short term provisions	209.08	69.53
Current tax liabilities(net)	-	1.03
Total Current liabilities	54.44	79.87
TOTAL EQUITY AND LIABILITIES	1,197.71	899.07
	6,719.31	5,604.25

For and on behalf of Board of Directors of
MEDICO INTERCONTINENTAL LIMITED



Tanvi

TANVI SHAH
Chairperson
DIN: 08192047

Place:-Ahmedabad
Date:-14/11/2024

MEDICO INTERCONTINENTAL LIMITED

CIN: L24100GJ1984PLC111413

Regd. Off: 1-5TH FLOOR, ADIT RAJ ARCADE NR KARMA SHRESHTHA TOWER, 100 FT RD, SATELLITE, Ahmedabad GJ 380015 IN

Tel No. 079-26742739

E-mail:- mail@medicointercontinental.com

Website: www.medicointercontinental.com

Unaudited Consolidated Cash Flow Statement for the half year ended 30 September, 2024

(Rs in Lakhs)

PARTICULARS		Half year ended 30.09.2024 (Unaudited)	Half year ended 30.09.2023 (Unaudited)
A.	CASH FLOW FROM OPERATING ACTIVITIES :		
a)	Net Profit/ (Loss) before tax	382.77	261.79
b)	OPERATING PROFIT BEFORE WORKING CAPITAL CHANGES	382.77	261.79
	<u>Adjustments For:</u>		
	Depreciation	28.97	13.59
	Finance cost	45.92	20.74
	Dividend received	-0.24	-0.16
	Interest received	-9.88	-6.25
	CASH GENERATED FROM OPERATIONS	447.55	289.72
	<u>Adjustments for</u>		
	Decrease/(Increase) in Inventories	309.70	179.11
	Decrease/(Increase) in Trade Receivables	-903.13	514.10
	Decrease/(Increase) in Short Term Loan and Advances	-96.47	-86.48
	Decrease/(Increase) in Other Current Assets/Non Current Assets	28.86	-630.11
	Increase/(Decrease) in Provisions and Other Current Liabilities	141.74	-3.98
	Increase/(Decrease) in Trade Payables	209.19	-443.69
	Increase/(Decrease) Current Financial Liabilities	0.00	0.00
	CASH GENERATION FROM OPERATING ACTIVITY	137.43	-181.33
	Income tax Paid Net	(127.58)	(107.60)
	NET CASH FROM/(USED IN) OPERATING ACTIVITIES	9.85	-288.93
B.	CASH FLOW FROM INVESTING ACTIVITIES:		
	Purchase of Fixed and Intangible assets	-194.56	-3.45
	Purchase/Sale Investments	0.00	0.00
	Payment for Intangible Assets	0.00	0.00
	Deposits (net)	-	-
	Interest Income	9.88	6.25
	Dividend Income	0.24	0.16
	NET CASH FROM/(USED IN) INVESTING ACTIVITIES	-184.44	2.96
C.	CASH FLOW FROM FINANCING ACTIVITIES:		
	Proceeds from issue of Shares	-	-
	Increase/(Decrease) in Loan and Advances	0.00	0.00
	Proceed from /(Repayment) of Long Term Borrowing net	531.75	101.79
	Proceed from /(Repayment) of Short Term Borrowing net	-23.63	9.03
	Dividend Paid	0.00	-10.00
	Finance Costs paid	-45.92	-20.74
	NET CASH FROM/(USED IN) FINANCING ACTIVITIES	462.19	80.08
	NET INCREASE IN CASH AND CASH EQUIVALENTS	287.59	-205.89
	CASH AND CASH EQUIVALENTS (At the beginning of the year)	336.52	678.54
	CASH AND CASH EQUIVALENTS (At the end of the year)	624.11	472.65

For and on behalf of Board of Directors of
MEDICO INTERCONTINENTAL LIMITED

Place: Ahmedabad
Date: 14/11/2024




 TANVI SHAH
 Chairperson
 DIN: 08192047